1,935 results match your criteria Primary CNS Lymphoma


[Central Neurological Diagnosis in Patients Infected with HIV in the Infectious Diseases Unit of University Hospital of Casablanca, Morocco].

Bull Soc Pathol Exot 2018 ;111(1):24-30

Service des maladies infectieuses, CHU de Ibn Rochd, Casablanca, Maroc.

The aim of this work is to study the epidemiology of central neurological system (CNS) diagnosed in the population of people living with HIV in the department of infectious diseases in UHC Ibn Rochd of Casablanca from January 2005 to May 2015. The demographic and clinical profile along with the outcome of these patients were studied. The data were collected from Nadis software. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3166/bspe-2018-0004DOI Listing
January 2018

Central Nervous System Lymphoma in a Patient with Chronic Lymphocytic Leukemia: A Case Report and Literature Review.

Cureus 2018 Nov 30;10(11):e3660. Epub 2018 Nov 30.

Neurosurgery, Stanford University School of Medicine, Stanford, USA.

Chronic lymphocytic leukemia (CLL) is the most common type of leukemia that affects older adults in the Western world. Symptomatic nervous system invasion in undiagnosed CLL is rare, poorly understood, challenging to treat, and associated with decreased survival. The average survival of CLL patients with central nervous system (CNS) involvement is 3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.3660DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364951PMC
November 2018

Diffuse large B-cell lymphoma of the central nervous system presenting as "lymphomatosis cerebri" and dementia in elderly man: Case report and review of the literature.

Medicine (Baltimore) 2019 Feb;98(6):e14367

Department of Hematology, Hospital Israelita Albert Einstein.

Rationale: Lymphomatosis cerebri is a rare form of PCNSL, characterized by diffuse infiltration of lymphoma cells in cerebral parenchyma, without mass-formation and mild or no contrast enhancement on magnetic resonance (MR) imaging. There are less than 50 cases described in the literature under the term Lymphomatosis cerebri.

Patient Concerns: A 74-year-old man presented to our service with progressive dementia for 12 months and accelerated cognitive decline within the last two months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014367DOI Listing
February 2019
1 Read

miR-370 Sensitizes TMZ Response Dependent of MGMT Status in Primary Central Nervous System Lymphoma.

Pathol Oncol Res 2019 Feb 2. Epub 2019 Feb 2.

Department of Neurosurgery, Hangzhou Xiasha Hospital, Sir Run Run Shaw Hospital, Medical College, Zhejiang University, Hangzhou, 310016, People's Republic of China.

Primary central nervous system lymphoma (PCNSL) is an aggressive and rare subtype of non-Hodgkin lymphoma, arising exclusively in the CNS with a poor prognosis. Previous evidence has proved that MGMT was a promising target involving in TMZ resistance of PCNSL. Our study described a new miR-370-mediated mechanism of MGMT regulation in PCNSL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12253-019-00605-4DOI Listing
February 2019
2 Reads

Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.

Lancet Haematol 2019 Feb;6(2):e100-e109

The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Background: Therapeutic approaches for B-cell malignancies continue to evolve, especially with regard to combination approaches. We assessed the safety and efficacy of the triplet ublituximab, umbralisib, and ibrutinib in patients with advanced B-cell malignancies.

Methods: We did an open-label, phase 1 study with dose-escalation and dose-expansion phases, at five centres in the USA. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23523026183021
Publisher Site
http://dx.doi.org/10.1016/S2352-3026(18)30216-3DOI Listing
February 2019
3 Reads

Lenalidomide in Combination with Intravenous Rituximab (REVRI) in Relapsed/Refractory Primary CNS Lymphoma or Primary Intraocular Lymphoma: a Multicenter Prospective "Proof of Concept" Phase II Study of the French Oculo-Cerebral Lymphoma (LOC) Network and the Lymphoma Study Association (LYSA).

Ann Oncol 2019 Jan 29. Epub 2019 Jan 29.

Department of Hematology, Institut Curie, Site Saint-Cloud, France.

Background: Primary central nervous system lymphomas (PCNSLs) are mainly diffuse large B-cell lymphomas (DLBCLs) of the non-germinal center B-cell (non-GCB) subtype. This study aimed to determine the efficacy of rituximab plus lenalidomide (R2) in DLBCL-PCNSL.

Patients And Methods: Patients with refractory/relapsed (R/R) DLBCL-PCNSL or primary vitreoretinal lymphoma (PVRL) were included in this prospective phase II study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz032DOI Listing
January 2019
1 Read

Primary central nervous system Hodgkin Lymphoma: A case discussion and a hypothesis on the etiology.

Avicenna J Med 2019 Jan-Mar;9(1):28-31

Hematogenix Laboratory Services, Tinley Park, IL, USA.

Hodgkin Lymphoma (HL) is a systemic disease with involvement of the cervical, supraclavicular, and mediastinal lymph nodes. It is commonly diagnosed in patients within the second and third decades of their lives. Diagnosis is usually made based on the distinct morphological and immunohistochemical characteristics, with the tissue biopsy being the cornerstone of workup. Read More

View Article

Download full-text PDF

Source
http://www.avicennajmed.com/preprintarticle.asp?id=240257
Publisher Site
http://dx.doi.org/10.4103/ajm.AJM_104_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335883PMC
January 2019
5 Reads

ALK Inhibitors in the Treatment of ALK Positive NSCLC.

Front Oncol 2018 9;8:557. Epub 2019 Jan 9.

Department of Radiation Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.

ALK inhibitors have shown positive advance in the treatment of ALK+ NSCLC. They have achieved better results in prolonging the progression free survival and improving quality of life in comparison to chemotherapy. We have assembled the evidence related to the efficacy and safety of these agents in the treatment of ALK positive NSCLC. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fonc.2018.00557/
Publisher Site
http://dx.doi.org/10.3389/fonc.2018.00557DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333640PMC
January 2019
3 Reads

FGL2 promotes tumor progression in the CNS by suppressing CD103 dendritic cell differentiation.

Nat Commun 2019 01 25;10(1):448. Epub 2019 Jan 25.

Department of Pediatrics-Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Few studies implicate immunoregulatory gene expression in tumor cells in arbitrating brain tumor progression. Here we show that fibrinogen-like protein 2 (FGL2) is highly expressed in glioma stem cells and primary glioblastoma (GBM) cells. FGL2 knockout in tumor cells did not affect tumor-cell proliferation in vitro or tumor progression in immunodeficient mice but completely impaired GBM progression in immune-competent mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-018-08271-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347641PMC
January 2019
3 Reads
10.742 Impact Factor

High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma: Data From the Japan Society for Hematopoietic Cell Transplantation Registry.

Biol Blood Marrow Transplant 2019 Jan 18. Epub 2019 Jan 18.

Department of Oncology/Hematology, Shimane University Hospital, Izumo, Japan.

High-dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT) has been shown to improve the prognosis of patients with central nervous system (CNS) lymphoma. We queried the Japan Society for Hematopoietic Cell Transplantation Registry for 2006 to 2015 to analyze the outcomes of 102 patients with primary CNS lymphoma (PCNSL) who underwent first HDT/ASCT. The median patient age was 54 years (range, 20 to 74 years), and 65 patients were treated in an upfront setting. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791193007
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2019.01.020DOI Listing
January 2019
11 Reads

Bilateral radiation therapy followed by methotrexate-based chemotherapy for primary vitreoretinal lymphoma.

Am J Hematol 2019 Jan 21. Epub 2019 Jan 21.

Department of Medicine, Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.

Primary vitreoretinal lymphoma (PVRL) is a subset of primary CNS lymphoma that presents as isolated ocular disease without brain involvement. Although ocular radiotherapy (RT) is an effective treatment for PVRL, the optimal treatment is uncertain. PVRL may later involve the brain in 56%-85% of patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25414DOI Listing
January 2019
1 Read

Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.

Lancet Oncol 2019 Feb 7;20(2):216-228. Epub 2019 Jan 7.

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.

Background: The prognosis for primary CNS lymphoma has improved with the use of high-dose methotrexate-based chemotherapy, but patient outcomes remain poor. Rituximab, a chimeric monoclonal antibody that targets the CD20 cell surface protein, has substantial activity in systemic CD20-positive diffuse large B-cell lymphoma, but its efficacy in primary CNS lymphoma is unknown and low penetration of the large rituximab molecule through the blood-brain barrier could limit its effect. We aimed to investigate the addition of rituximab to a high-dose methotrexate-based chemotherapy regimen in patients with newly diagnosed primary CNS lymphoma. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045183074
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(18)30747-2DOI Listing
February 2019
9 Reads

Staging identifies non-CNS malignancies in a large cohort with newly diagnosed lymphomatous brain lesions.

Leuk Lymphoma 2019 Jan 10:1-5. Epub 2019 Jan 10.

a Department of Neurology , Memorial Sloan Kettering Cancer Center , New York , NY , USA.

Lymphomatous brain lesions can represent primary central nervous system (CNS) lymphoma or secondary involvement as part of systemic disease (SCNSL). In this study, we characterize staging evaluations in a large patient cohort with newly-diagnosed brain lymphomas, to determine the frequency of SCNSL and secondary malignancies. This retrospective review includes 262 patients with newly-diagnosed lymphomatous CNS lesions evaluated at Memorial Sloan Kettering Cancer Center between 2006 and 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1563294DOI Listing
January 2019
3 Reads

Central Nervous System Peripheral T Cell Lymphoma Manifesting as Lymphomatosis Cerebri That Was Misdiagnosed as Neuro-Behçet's Disease: A Case Report.

Case Rep Oncol 2018 Sep-Dec;11(3):806-813. Epub 2018 Nov 29.

Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan.

Background: Lymphomatosis cerebri (LC) is a unique form of primary central nerves lymphoma (PCNSL), which presents as diffuse infiltration of lymphoma cells characteristically in the white matter rather than tumor formation. However, the involvement of central nervous system (CNS) is unclear because of the lack of contrast enhancement.

Case Presentation: We treated a 53-year-old woman with LC and brain lesions resembling neuro-Behcet's disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323408PMC
November 2018
5 Reads

Post-transplant primary central nervous system lymphoma after Epstein-Barr virus cerebellitis.

J Neurovirol 2019 Jan 3. Epub 2019 Jan 3.

Division of Neurology, Mayo Clinic Arizona, 13400 East Shea Boulevard, Scottsdale, AZ, 85259, USA.

Post-transplantation lymphoproliferative disorder (PTLD) is a complication of solid organ and hematopoietic stem cell transplantation. Cases with isolated central nervous system (CNS) disease are rare. Epstein-Barr virus (EBV) plays a causative role. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13365-018-0711-8DOI Listing
January 2019

Cultured Cells Isolated from CNS Indolent B-Cell Lymphoma Have Characteristics of Mesenchymal Stem Cells: A Clinical Case and Scientific Research.

Int J Hematol Oncol Stem Cell Res 2018 Jul;12(3):169-174

Laboratory of Clinical Immunology, University Hospital "St. Ivan Rilski", Department of Clinical Laboratory and Clinical Immunology, Medical University of Sofia, Sofia, Bulgaria.

The case report presented here describes the culturing and characterization of mesenchymal stem cells (MSCs) isolated from a primary indolent B-cell lymphoma, located in the CNS of an immunocompetent patient. The presence of such cells in the tumor mass can further elucidate the pathogenesis of the disease and reveal possible future approaches for its treatment. We present a case report of a 61-year-old immunocompetent woman who had an episode of confusion with numbness in the right leg and the right arm, slurred and dysarthric speech and urine incontinence. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305270PMC
July 2018
3 Reads

Solitary Primary CNS Lymphoma mimicking third ventricular colloid cyst- case report and review of the literature.

World Neurosurg 2018 Dec 19. Epub 2018 Dec 19.

Primary central nervous system lymphoma (PCNSL) is a rare malignant tumor of the central nervous system and it is associated with poor prognosis, it accounts for 0.7-0.9% of all lymphomas and for only 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2018.12.026DOI Listing
December 2018

CSF TACI and BAFF levels in patients with primary CNS lymphoma as novel diagnostic biomarkers.

Ann Clin Transl Neurol 2018 Dec 19;5(12):1611-1616. Epub 2018 Oct 19.

Department of Neurology Graduate School of Medical Sciences Kumamoto University Kumamoto Japan.

We used an enzyme-linked immunosorbent assay to measure pretreatment B cell-activating factor belonging to the tumour necrosis factor family (BAFF) and transmembrane activator and CAML-interactor (TACI) levels in CSF and serum collected from patients with primary central nervous system lymphoma (PCNSL) and control groups. The decision tree analysis of CSF TACI and BAFF levels for patients with a PCNSL diagnosis showed 100% sensitivity and 100% specificity when we attempted to differentiate PCNSL from glioblastoma and CNS inflammatory diseases. The combination of CSF TACI and BAFF levels may thus be a novel and useful diagnostic biomarker of PCNSL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acn3.668DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292192PMC
December 2018

AIDS-Associated Malignancies.

Cancer Treat Res 2019 ;177:1-21

Department of Dermatology, University of Texas Health Sciences Center at Houston, Houston, TX, 77030, USA.

Malignancies were one of the earliest recognized manifestations that led to the description of the acquired immune deficiency syndrome (AIDS). The majority of cancers in AIDS patients are associated with coinfection with oncogenic viruses, such as Epstein-Barr virus, human herpesvirus 8, and human papillomavirus, with resulting malignancies occurring secondary to diminished immune surveillance against viruses and virus-infected tumor cells. Over 50% of AIDS lymphomas are associated with Epstein-Barr virus (EBV) and/or HHV8 infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-030-03502-0_1DOI Listing
January 2019
6 Reads

Intrathecal Central Nervous System Prophylaxis in Patients With Diffuse Large B-cell Lymphoma at an Academic Healthcare System.

Clin Lymphoma Myeloma Leuk 2019 Feb 17;19(2):89-94. Epub 2018 Nov 17.

Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA.

Introduction: Intrathecal chemoprophylaxis is often administered to patients with diffuse large B-cell lymphoma (DLBCL) to lower the rates of central nervous system (CNS) relapse, although its benefit has not been well-described. Prognostic models, including the CNS-International Prognostic Index (IPI), have been developed to aid in identifying patients at highest risk for CNS relapse.

Patients And Methods: We evaluated 112 patients diagnosed with DLBCL from 2009 to 2016 at Emory Healthcare and classified them as high (n = 44) or low risk (n = 68) for CNS relapse and compared CNS prophylaxis rates and relapse rates between groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.11.014DOI Listing
February 2019

Cerebrospinal fluid interleukin (IL)-10 and IL-10:IL-6 ratio as biomarkers for small B-cell lymphoproliferations with leptomeningeal dissemination.

Semin Hematol 2018 Oct 6;55(4):179-181. Epub 2017 Jul 6.

Department of Biological Hematology, Pitie-Salpetriere Hospital, Paris, France; Centre de Recherche des Cordeliers, Cell Death and Drug Resistance in Lymphoproliferative Disorders, Paris, France.

We here report for the first time that low levels of interleukin (IL)-10 do not exclude lymphomatous meningitis (LM) in B-cell lymphoproliferative disorders (CLPD). Unexpectedly, IL-10 levels and IL-10:IL-6 ratio in CLPD differed from the levels observed in diffuse large B-cell lymphoma (DLBCL). We report the usefulness of adding the IL-10:IL-6 ratio in order to potentially reveal more aggressive lymphomas: either a transformation or an association with another "hidden" lymphoma such as primary CNS lymphoma (PCNSL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminhematol.2017.06.005DOI Listing
October 2018
3 Reads

Primary CNS lymphoma patient-derived orthotopic xenograft model capture the biological and molecular characteristics of the disease.

Blood Cells Mol Dis 2019 Mar 16;75:1-10. Epub 2018 Nov 16.

Institut Curie, Site Saint-Cloud Hematology, Saint-Cloud, France. Electronic address:

Primary CNS lymphomas (PCNSL) are rare and poor prognosis diffuse large B-cell lymphomas. Because of the brain tumor environment and the restricted distribution of drugs in the CNS, specific PCNSL patient-derived orthotopic xenograft (PDOX) models are needed for preclinical research to improve the prognosis of PCNSL patients. PCNSL patient specimens (n = 6) were grafted in the caudate nucleus of immunodeficient nude mice with a 83% rate of success, while subcutaneous implantation in nude mice of human PCNSL sample did not generate lymphoma, supporting the role of the brain microenvironment in the PCNSL physiopathology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcmd.2018.11.005DOI Listing
March 2019
1 Read

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.

Lancet Haematol 2018 Dec;5(12):e609-e617

Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD, USA. Electronic address:

Background: MYC gene rearrangement is present in approximately 10% of aggressive B-cell lymphomas, with half also harbouring a BCL2 gene rearrangement. Multiple retrospective studies of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone) have shown a worse outcome in patients with MYC rearrangement (alone or with rearrangement of BCL2 or BCL6, or both) than in patients without MYC rearrangement, and suggest improved outcomes after more intensive treatment. We aimed to determine the outcome of dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab; DA-EPOCH-R), an intensive infusional treatment regimen, in untreated aggressive B-cell lymphoma with MYC rearrangement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(18)30177-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342507PMC
December 2018
1 Read

Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018.

Am J Hematol 2019 Mar 5;94(3):291-298. Epub 2018 Dec 5.

Division of Hematology, Mayo Clinic, Rochester, Minnesota.

Vitreoretinal lymphoma (VRL) management remains a challenge. We present 72 patients with VRL, diagnosed at Mayo Clinic between 1990-2018. Three nondiffuse large B-cell lymphoma (DLBCL) histology cases were excluded. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25350DOI Listing
March 2019
2 Reads

Methotrexate induces astrocyte apoptosis by disrupting folate metabolism in the mouse juvenile central nervous system.

Toxicol Lett 2019 Feb 28;301:146-156. Epub 2018 Nov 28.

Department of Pharmacy, Hangzhou Medical College, Hangzhou 310053, China. Electronic address:

Methotrexate (MTX) is a folic acid antagonist and widely used for acute lymphoblastic leukemia (ALL) in children. MTX is associated with acute and chronic neurotoxicity during treatment, however the underlying mechanism is still poorly understood. In this study we investigate whether MTX is neurovirulent to astrocytes in the Central Nervous System (CNS) of adolescent mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.toxlet.2018.11.016DOI Listing
February 2019
1 Read

Introduction of novel agents in the treatment of Primary CNS Lymphoma.

Neuro Oncol 2018 Nov 13. Epub 2018 Nov 13.

Departments of Neurology and Radiation Oncology, Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA.

Novel insights into the pathophysiology of Primary Central Nervous System Lymphoma (PCNSL) have identified the B-cell receptor and Toll-like receptor pathway as well as immune evasion and suppressed tumor immune microenvironment as a key mechanism in the pathogenesis of PCNSL. Small molecules and novel agents targeting these aberrant pathways have been introduced into clinical trials targeting the recurrent or refractory PCNSL patient population. Agents like the Bruton Tyrosine Kinase (BTK) inhibitor ibrutinib or immunomodulatory drugs (IMiDs) like pomalidomide and lenalidomide have shown promising high response rates in the salvage setting. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/advance-article/doi/
Publisher Site
http://dx.doi.org/10.1093/neuonc/noy193DOI Listing
November 2018
13 Reads

Comprehensive Approach to Diagnosis and Treatment of Newly Diagnosed Primary CNS Lymphoma.

Neuro Oncol 2018 Nov 12. Epub 2018 Nov 12.

Departments of Neurology and Radiation Oncology, Division of Hematology and Oncology, Boston, MA.

Primary central nervous system (CNS) lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma that affects the brain parenchyma, spinal cord, eyes, and cerebrospinal fluid without evidence of systemic, non-CNS involvement. PCNSL is uncommon and only a few randomized trials have been completed in the first-line setting. Over the past decades, the prognosis of PCNSL has improved mainly due to the introduction and wide-spread use of high-dose methotrexate, which is now the backbone of all first-line treatment polychemotherapy regimens. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/advance-article/doi/
Publisher Site
http://dx.doi.org/10.1093/neuonc/noy192DOI Listing
November 2018
23 Reads

Management and survival trends for adult patients with malignant gliomas in the setting of multiple primary tumors: a population based analysis.

J Neurooncol 2019 Jan 5;141(1):213-221. Epub 2018 Nov 5.

National Skull Base Center, Thousand Oaks, CA, USA.

Introduction: The impact of multiple primary tumors, in the setting of malignant glioma (MG), has not been heavily explored.

Methods: We extracted demographics and clinical data from the SEER-18 registry for adult patients with MGs. The cases were separated based on the sequence of MG diagnosis relative to the other primary tumors: Group (A) One primary only or first primary of multiple primaries and Group (B) second primary or subsequent primary tumor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-018-03028-4DOI Listing
January 2019
9 Reads

CD79B mutations in primary vitreoretinal lymphoma: Diagnostic and prognostic potential.

Eur J Haematol 2019 Feb 23;102(2):191-196. Epub 2018 Nov 23.

Department of Laboratory Molecular Genetics of Hematology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.

Objective: Primary vitreoretinal lymphoma (PVRL) is a rare type of lymphoma wherein the lesions are limited to the eyes. PVRL is difficult to diagnose because of the challenges related to obtaining sufficient samples for biopsy. Moreover, PVRL has poor outcomes and often leads to the development of central nervous system (CNS) lesions during its course. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.13191
Publisher Site
http://dx.doi.org/10.1111/ejh.13191DOI Listing
February 2019
12 Reads

Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues.

Ann Diagn Pathol 2019 Feb 2;38:6-10. Epub 2018 Oct 2.

Neogenomics, Aliso Viejo, CA, United States of America; M.D. Anderson Cancer Center, University of Texas, Department of Hematopathology, Houston, TX, United States of America. Electronic address:

The recent 2017 update of the World Health Organization classification of lymphomas has significant changes from the previous edition. Subtypes of large B cell lymphoma and related aggressive B cell lymphomas are addressed. Clinicopathological features of entities as related to morphology, immunophenotype, cell of origin, and molecular/genetic findings are reviewed with emphasis on changes or updates in findings. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10929134183028
Publisher Site
http://dx.doi.org/10.1016/j.anndiagpath.2018.09.014DOI Listing
February 2019
15 Reads

Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy.

Adv Radiat Oncol 2018 Oct-Dec;3(4):639-646. Epub 2018 Jul 12.

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Background: For patients with primary diffuse large B-cell lymphoma of the central nervous system (PCNSL), whole-brain radiation therapy (WBRT) to doses of ≥45 Gy are often given after a partial response (PR) to methotrexate-based induction chemotherapy. We conducted an exploratory analysis to determine whether lower-dose WBRT, given with a boost to sites of persistent disease, might be a reasonable alternative.

Methods And Materials: We retrospectively reviewed the records of 22 patients with PCNSL who received WBRT, with or without a boost, after methotrexate-based induction chemotherapy. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S24521094183012
Publisher Site
http://dx.doi.org/10.1016/j.adro.2018.07.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200878PMC
July 2018
5 Reads

Genetic evidence implies that primary and relapsed tumors arise from common precursor cells in primary central nervous system lymphoma.

Cancer Sci 2019 Jan 18;110(1):401-407. Epub 2018 Nov 18.

Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan.

Primary central nervous system lymphoma (PCNSL) is a rare subtype of lymphoma that arises within the brain or the eyes. PCNSL recurs within the central nervous system (CNS) in most relapsed cases, whereas extra-CNS relapse is experienced in rare cases. The present study aimed at identifying the presence of common precursor cells (CPC) for primary intra- and relapsed extra-CNS tumors, and further assessing the initiating events in bone marrow (BM). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13848DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317941PMC
January 2019
2 Reads

Successful nivolumab therapy in an allogeneic stem cell transplant child with post-transplant lymphoproliferative disorder.

Pediatr Transplant 2018 12 21;22(8):e13302. Epub 2018 Oct 21.

Department of Pediatric Hematology and Stem Cell Transplantation, Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary.

Primary CNS PTLD is an extremely rare complication after allogeneic HSCT. At our centre, an 11-year-old patient developed nausea, vomiting, and diplopy on day +82 following HSCT. On brain MRI, multiple white matter lesions were seen. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/petr.13302
Publisher Site
http://dx.doi.org/10.1111/petr.13302DOI Listing
December 2018
10 Reads

Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma.

Curr Hematol Malig Rep 2018 Dec;13(6):543-554

Department of Hematologic Malignancies and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.

Purpose Of The Review: The ligation of PD-1 with PD-L1 activates a critical immune checkpoint leading to T cell dysfunction, exhaustion, and tolerance. Anti-PD-1 or anti-PD-L1 monoclonal antibodies can reverse the immune checkpoint, releasing the brake on T cell responses. We provide a comprehensive review of the literature on the activity of checkpoint inhibitors in lymphoma. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11899-018-0484-4
Publisher Site
http://dx.doi.org/10.1007/s11899-018-0484-4DOI Listing
December 2018
23 Reads

Intraocular involvement is associated with a high risk of disease relapse in primary central nervous system lymphoma.

Oncol Rep 2019 Jan 11;41(1):397-404. Epub 2018 Oct 11.

Department of Hematology, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China.

The aim of the present study was to prospectively evaluate the recurrence and survival outcome of primary central nervous system lymphoma (PCNSL) with intraocular involvement. For this purpose, a prospective cohort of 103 pathologically confirmed patients with PCNSL was enrolled in this study. Ophthalmologic examinations were performed both at diagnosis and during follow‑up. Read More

View Article

Download full-text PDF

Source
http://www.spandidos-publications.com/10.3892/or.2018.6781
Publisher Site
http://dx.doi.org/10.3892/or.2018.6781DOI Listing
January 2019
12 Reads

MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type.

Ann Hematol 2019 Jan 11;98(1):169-173. Epub 2018 Oct 11.

Pathology and Stem Cell Research Center, Afzalipour Medical School, Kerman University of Medical Sciences, Kerman, Iran.

Primary central nervous system lymphoma (PCNSL) is a rare specific subtype of non-Hodgkin lymphoma limited to the brain, leptomeninges, spinal cord, or eyes without any systemic presentation and relapse which mostly takes place in CNS. In more than 95% of patients, it is of diffuse large B cell lymphoma (DLBCL) type. Categorizing PCNSL to germinal center cell like or activated B cell like, as we usually do for DLBCL NOS, may not be applicable for predicting outcome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-018-3498-zDOI Listing
January 2019
8 Reads

Primary breast diffuse large B-cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure.

Cancer Sci 2018 Dec 11;109(12):3943-3952. Epub 2018 Nov 11.

Department of Medical Oncology, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Primary breast diffuse large B-cell lymphoma (PB-DLBCL) is a rare subtype of DLBCL with limited data on patterns of failure. This multicenter study aimed to define the optimum treatment strategy and patterns of failure for PB-DLBCL patients. We retrospectively reviewed data on 108 PB-DLBCL patients from 21 Chinese medical centers. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/cas.13828
Publisher Site
http://dx.doi.org/10.1111/cas.13828DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6272095PMC
December 2018
4 Reads

Long-term outcomes of rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNS.

Int J Hematol Oncol 2017 Dec 26;6(4):113-121. Epub 2018 Jan 26.

Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Perelman Center for Advanced Medicine, 3400 Civic Center Blvd, 2 West Pavilion, Philadelphia, PA 19104, USA.

Aim: To describe the long-term outcomes of patients with lymphoma in the CNS treated with rituximab, temozolomide and high-dose methotrexate without consolidation therapy.

Patients & Methods: A retrospective cohort study of 46 consecutive patients with primary CNS lymphoma (PCNSL, 27 patients) or secondary CNS involvement of diffuse large B-cell lymphoma (DLBCL, 19 patients) who were treated with rituximab on day 1 in combination with high-dose methotrexate (days 1 and 15) and temozolomide (days 1-5) in 28-day cycles without further consolidation.

Results: Median follow-up was 21. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijh-2017-0020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171986PMC
December 2017
3 Reads

Primary diffuse large B-cell lymphoma of the CNS: a rare case of spontaneous remission.

Int J Hematol Oncol 2017 Nov 20;6(3):69-73. Epub 2017 Nov 20.

Abramson Cancer Center, Hospital of the University of Pennsylvania, 12 South PCAM, 3400 Civic Center Blvd, PA 19104, USA.

There is no consensus on the optimal therapy for primary CNS lymphoma. Conventional treatment modalities include chemotherapy and radiation therapy, which carry significant risks of morbidity and mortality. In systemic lymphomas, there are situations where non-Hodgkin lymphomas have resolved spontaneously. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijh-2017-0009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171994PMC
November 2017
2 Reads

Detection of the p.L265P Mutation in the CSF of a Patient With Secondary Central Nervous System Lymphoma.

Front Oncol 2018 20;8:382. Epub 2018 Sep 20.

Department of Pathology and Laboratory Medicine, University of Texas Health Science Center, Houston, TX, United States.

Primary Central Nervous System Lymphoma (PCNSL) and Metastatic (or Secondary) Central Nervous System Lymphoma (MCNSL) are rare central nervous system (CNS) malignancies that exhibit aggressive clinical behavior and have a poor prognosis. The majority of CNS lymphomas are histologically classified as diffuse large-B cell lymphoma (DLBCL). DLBCL harbors a high frequency of mutations in and . Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fonc.2018.00382/
Publisher Site
http://dx.doi.org/10.3389/fonc.2018.00382DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158312PMC
September 2018
13 Reads

Canine Cerebral Intravascular Lymphoma: Neuropathological and Immunohistochemical Findings.

Vet Pathol 2018 Oct 5:300985818806059. Epub 2018 Oct 5.

1 Department of Veterinary Science, University of Pisa, Pisa, Italy.

Intravascular lymphoma (IVL) is a rare angiotropic large-cell lymphoma in which neoplastic lymphocytes proliferate within the lumina of small blood vessels in the absence of a primary extravascular mass or leukemia. This study included 10 cases of canine IVL restricted to the CNS. Dogs had an average age of 8 years and neurological signs mainly referred to brain involvement such as depression, seizures, and ambulatory deficits. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0300985818806059DOI Listing
October 2018
12 Reads

Array-based profiling of the lymphoma cell DNA methylome does not unequivocally distinguish primary lymphomas of the central nervous system from non-CNS diffuse large B-cell lymphomas.

Genes Chromosomes Cancer 2019 01 29;58(1):66-69. Epub 2018 Nov 29.

Institute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, Germany.

Primary lymphomas of the central nervous system (PCNSL) are diffuse large B-cell lymphomas (DLBCLs) confined to the central nervous system (CNS). We here performed array-based DNA methylation analyses of 26 PCNSL and 78 DLBCL and validated our findings in an independent dataset. We identified 2847 CpGs differentially methylated between PCNSL and non-CNS-DLBCL. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/gcc.22687
Publisher Site
http://dx.doi.org/10.1002/gcc.22687DOI Listing
January 2019
2 Reads

Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma.

Blood 2018 Nov 27;132(21):2240-2248. Epub 2018 Sep 27.

Mayo Clinic, Rochester, MN.

The combination of pomalidomide (POM) and dexamethasone (DEX) was evaluated for relapsed/refractory primary central nervous system lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL) to determine the maximal tolerated dose (MTD) of POM as the primary objective, and overall response rate (ORR), progression-free survival (PFS), and safety profile as secondary objectives. A cohorts-of-3 study design was used with a dose-escalation schedule consisting of POM (3, 5, 7, or 10 mg) orally daily for 21 days every 28 days and DEX 40 mg orally every week. After 2 cycles, POM was continued alone until disease progression, intolerance, or subject withdrawal. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-02-835496DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6265643PMC
November 2018
11 Reads

Hyper--glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma.

Blood 2018 Dec 24;132(26):2744-2753. Epub 2018 Sep 24.

José Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany.

To address the role of chronic antigenic stimulation in primary central nervous system lymphoma (PCNSL), we searched for autoantigens and identified sterile α-motif domain containing protein 14 (SAMD14) and neural tissue-specific F-actin binding protein I (neurabin-I) as autoantigenic targets of the B-cell receptors (BCRs) from 8/12 PCNSLs. In the respective cases, SAMD14 and neurabin-I were atypically hyper--glycosylated (SAMD14 at ASN339 and neurabin-I at ASN1277), explaining their autoimmunogenicity. SAMD14 and neurabin-I induced BCR pathway activation and proliferation of aggressive lymphoma cell lines transfected with SAMD14- and neurabin-I-reactive BCRs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-03-836932DOI Listing
December 2018
10 Reads

Adrenal relapse of primary central nervous system diffuse large B-cell lymphoma: A case report.

Medicine (Baltimore) 2018 Sep;97(38):e12482

Department of Pathology, Duke University Medical Center, Durham, NC.

Rationale: Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma with a dismal outcome. Most patients relapse in intracranial sites and <5% of patients relapse in extracranial sites. Here, we present the first case of PCNSL with an adrenal relapse. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000012482DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160128PMC
September 2018
4 Reads

Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma.

CNS Oncol 2018 07 17;7(3):CNS19. Epub 2018 Sep 17.

Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA.

Aim: To establish the safety and feasibility of rapidly infusing rituximab over 90 min in patients with primary CNS lymphoma (PCNSL).

Patients & Methods: We retrospectively reviewed all patients with PCNSL who received rapid rituximab infusions (RRI) from January 2016 to January 2017. Primary end point was incidence of infusion reactions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/cns-2018-0001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200062PMC

Efficacy of the Nordic and the MSKCC chemotherapy protocols on the overall and progression-free survival in intracranial PCNSL.

Blood Cells Mol Dis 2018 Nov 30;73:25-32. Epub 2018 Aug 30.

Department of Neurosurgery, Oslo University Hospital, Oslo, Norway; Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Background: To compare the Nordic and the Memorial Sloan-Kettering Cancer Center (MSKCC) chemotherapy protocols for Overall Survival (OS) and Progression-Free Survival (PFS) for intracranial primary CNS lymphoma (PCNSL).

Methods: A prospective database at Oslo University Hospital of PCNSL was reviewed over a 12-year period (2003-2014).

Results: Overall, 79 patients with PCNSL were identified, of whom 57 received chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcmd.2018.08.005DOI Listing
November 2018

Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.

Ann Oncol 2018 Nov;29(11):2214-2222

Division of Medical Oncology, University of Colorado, Aurora, USA.

Background: The phase III ALEX study in patients with treatment-naive advanced anaplastic lymphoma kinase mutation-positive (ALK+) non-small-cell lung cancer (NSCLC) met its primary end point of improved progression-free survival (PFS) with alectinib versus crizotinib. Here, we present detailed central nervous system (CNS) efficacy data from ALEX.

Patients And Methods: Overall, 303 patients aged ≥18 years underwent 1:1 randomization to receive twice-daily doses of alectinib 600 mg or crizotinib 250 mg. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdy405DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290889PMC
November 2018
8 Reads